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Figure  6. Detection of AFP-negative HCC by 5 HCC DNA markers in (A) 
tissue and (B) 3 cfDNA markers in urine. Marker distribution in individual 
HCC with available AFP value in our study population. Filled boxes 
represent a marker detected "positive", higher than cut-off value at 90% 
specificity distinguishing HCC from cirrhosis or positive for AFP. Empty 
boxes represent a marker value below the cut-off at 90% specificity or 
negative for AFP. 
 
Hepatocellular carcinoma (HCC) or liver cancer is an aggressive disease and one 
of the fastest growing cancers by incidence in the United States. Early detection 
is the key for effective treatment of HCC as the 5-year survival rate is 26% in 
early stage HCC as compared to only 2% when found after spreading to distant 
organs. The current marker, alpha-feto protein (AFP) and its fucosylated 
glycoform, L3, are of limited value with only 40-60% sensitivity.  
 
Urine contains fragmented, cell-free, cancer associated DNA, both mutated and 
methylated, derived from the circulation of cancer patients (Lin, Dhillon et al. 2011, 
Song, Jain et al. 2012, Jain, Xie et al. 2015) and the concentration of tumor-derived 
DNA in plasma and in urine is similar in patients with tumors (Su, Wang et al. 2008).  
Results 
Urine samples were collected with written informed consent and institutional review board 
approvals from National Cheng Kung University (Tainan, Taiwan), Tzu-Chi Hospital, (Hualien, 
Taiwan), and Thomas Jefferson University Hospital (Philadelphia, PA), at visits with a 
hepatologist,  Note the samples from TJU were barcoded for disease status as a blinded 
study. Total urine DNA was isolated (Su, Wang et al. 2004) and the low molecular weight 
urine DNA, DNA less than 1 kb, was obtained from total urine DNA using carboxylated 
magnetic beads (Agentcourt Bioscience Corporation) as previously developed by us (Su, 
Wang et al. 2008). Bisulfite (BS) treatment was performed using EZ DNA Methylation-
Lightning™ Kit (Zymo Research) following manufacturer’s guidelines. In order to detect 
circulation-derived, cell-free DNA markers in urine, we have developed short amplicon (~50 
bp) PCR-based assays for mutations in TP53 (249T) (Lin, Dhillon et al. 2011), CTNNB1 
(exon 3 - codons 32-37), TERT (-124 promoter) and for aberrant DNA methylation in GSTP1 
(mGSTP1) and RASSF1A (mRASSF1A) (Jain, Xie et al. 2015).  
Case 1: Detection of a primary HCC 
Figure 3: Retrospective analysis of urinary DNA markers plus serum AFP 
collected during doctor visits of a 55 year old male with HBV-cirrhosis 
who developed HCC that was undetectable by serum AFP but elevated  
urine CTNNB1 mutation levels and was treated with microwave ablation. 
The patient, however, had a recurrence of HCC 4 months post treatment. 
While mGSTP1 and CTNNB1 mutation levels in urine declined post-
treatment, urinary mRASSF1A, TERT 124 mutation and TP53 249T 
mutation levels continue to rise concurrent with the recurrence. 
Figure 5: Retrospective analysis of urinary DNA markers plus serum AFP 
collected during doctor visits of a 53 year old male with HBV-
hepatitis/early cirrhosis who developed HCC that was detectable by 
serum AFP and was treated with microwave ablation.  The patient, 
however, had a recurrence of HCC 2 months post MW ablation.  While 
mGSTP1 level in urine declined post treatment, urinary mRASSF1A and 
TERT 124 mutation levels continued to rise concurrent with the 
recurrence. 
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Figure. 1. LMW urine DNA 
co-migrates with 1-2 
nucleosomal sized DNA 
from serum and does not 
exist as naked DNA in urine. 
This indicates that the 
source of this circulation-
derived DNA in urine is 
predominantly from 
apoptotic cells 
Pathway Gene DNA 
Alteration 
Incidence 
(%) 
Reported in 
circulation (Yes/No) 
Wnt signalling 
APC  M/G 80-93/ 1-2 Yes  
SFRP1  M 42-63 Yes 
CTNNB1 G 19-33  No 
AXIN1 G 13-15  No 
Cell cycle/ Apoptosis 
RASSF1A  M 55-85 Yes  
CDKN2A M/G 50-70/ 5-10 Yes  
TP53  G 20-50 Yes  
IRF2  G 5  No 
Detoxification  GSTP1 M 38-80 Yes 
Telomerase maintainance TERT G 59  No 
Table 1. Frequent genetic mutations (G) and epigenetic aberrant DNA 
methylations (M) reported in HCC tissues. 
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Microwave ablation 
Figure 2: Retrospective analysis of DNA biomarkers from urine samples, 
plus serum AFP and serum HBV viral load  levels  collected during doctor 
visits of a 74 year-old male with HBV-cirrhosis who developed HCC that 
was undetectable by serum AFP  and was treated with microwave 
ablation. Urinary mRASSF1A DNA and TERT 124 mutated DNA levels 
started to elevate 6 months prior to HCC detection by MRI and declined 
post treatment. TP53 249T  mutation level rose with the appearance of 
HCC and declined post treatment. 
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Figure 4: Retrospective analysis of urinary DNA biomarkers and serum 
AFP levels collected during doctor visits of a 73 year old male with HBV-
cirrhosis and HCC that was treated with TACE. Samples were collected 
before TACE at the first time point. The DNA markers were undetectable 
but serum AFP was slightly elevated at 89 ng/ml and declined to baseline 
after TACE therapy. HCC recurrence was detected by MRI 11-13 months 
after TACE treatment. TERT 124 mutation levels are elevated 6 months 
prior to recurrence detection by MRI. mRASSF1A , TP53 249 T mutation, 
and serum AFP levels rise with the appearance of recurrent nodule and 
declined post treatment. This recurrence was also treated with TACE. 
Note, MRI at 11 months was not definitive.  Urine mGSTP1 , TERT 124 
levels rise 4 months post repeat TACE concurrent with the appearance of 
a LIRADS category 3 lesion on MRI.  
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Results 
(A) HCC tissue biomarker distribution 
(B)  HCC urine biomarker distribution 
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Develop a urine test using a panel of select genetic and epigenetic 
markers for the early detection of  primary and recurrent HCC. 
Objective 
Recurrence 
A total of 10 cases with treated HCC were monitored by 
serum AFP and urine DNA biomarkers in a blinded study. Of 
the 10, 4 developed recurrence during the study. HCC-
specific urine DNA markers were detected in 3 of 4 patients 
six months prior to MRI diagnosis and in one patient 
concurrent with MRI diagnosis.   
Fifteen cirrhosis and nine hepatitis patients were 
monitored every six months for HCC. In this group, one 
patient developed primary HCC and the urine DNA 
biomarkers were detected six months prior to MRI diagnosis 
in a blinded study. 
The urine test could lead to a paradigm shift for screening 
and effective management of primary and recurrent HCC and 
for personalized disease management. 
